{
    "clinical_study": {
        "@rank": "159980", 
        "brief_summary": {
            "textblock": "To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to:\n\n      Laboratory (immunologic defects):\n\n        -  Comparison of total helper and suppressor T-cell numbers among the groups.\n\n        -  Comparison of changes in natural killer cell activity.\n\n        -  Comparison of other laboratory findings among the groups.\n\n      Clinical changes:\n\n        -  Comparison of the frequency of opportunistic infections among the groups.\n\n        -  Comparison of the frequency of the development of AIDS-related malignancies.\n\n        -  Comparison of other clinical manifestations relative to severity and time of onset."
        }, 
        "brief_title": "A Study of Isoprinosine in Patients With Severe AIDS", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and\n        severe gastric ulcer are excluded.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Steroids.\n\n          -  Cytotoxic immunosuppressive agents.\n\n          -  Radiotherapy.\n\n        The following are excluded:\n\n          -  Critically ill patients.\n\n          -  Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.\n\n          -  Patients who have received any other immunotherapy.\n\n          -  Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction,\n             and severe gastric ulcer.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any other immunotherapy.\n\n        Patients with severe AIDS and specified laboratory immunologic defects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002295", 
            "org_study_id": "008F", 
            "secondary_id": "ISO-141-USA"
        }, 
        "intervention": {
            "intervention_name": "Inosine pranobex", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Inosine Pranobex"
        }, 
        "keyword": [
            "Infusions, Intravenous", 
            "Drug Evaluation", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Biological Availability"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92656"
                }, 
                "name": "Newport Pharmaceuticals International Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Severe Acquired Immunodeficiency Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002295"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Pharmaceuticals International", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Newport Pharmaceuticals International Inc": "33.599 -117.699"
    }
}